Annual report pursuant to Section 13 and 15(d)

License/Supplier Agreements (Details)

v3.21.1
License/Supplier Agreements (Details) - USD ($)
$ in Millions
1 Months Ended
Dec. 31, 2019
Oct. 29, 2018
Jun. 17, 2015
Revogenex License [Member]      
Contractual Obligation, Maximum Future Payments     $ 3.0
IV Tramadol [Member] | Fortress [Member]      
Payments to Acquire in Process Research and Development     3.0
IV Tramadol [Member] | Fortress [Member] | Upfront Payment [Member]      
Payments to Acquire in Process Research and Development     2.0
IV Tramadol [Member] | Fortress [Member] | Additional Payment [Member]      
Payments to Acquire in Process Research and Development     $ 1.0
Polpharma [Member]      
Payments to Acquire in Process Research and Development   $ 2.0  
New Drug Application [Member] | Revogenex License [Member]      
Payments to Acquire in Process Research and Development $ 1.0